Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

While congenital anomalies account for the vast majority of childhood cardiac problems in resource-rich nations, acquired cardiovascular pathology remains a formidable source of morbidity and mortality. Kawasaki disease has supplanted acute rheumatic fever as the leading cause of acquired heart disease among children in industrialized countries. Meanwhile, Acute Rheumatic Fever (ARF) continues to cause widespread cardiac injury and chronic rheumatic heart disease globally. A thorough understanding of their clinical diagnostic criteria, immunological mechanisms, and pharmacological protocols is essential for specialist pediatric practice.

---

Kawasaki Disease: Epidemiology and Pathophysiology

Kawasaki disease (mucocutaneous lymph node syndrome) is an acute, self-limited, systemic medium-vessel necrotizing vasculitis with an extraordinary predilection for the coronary arteries. First described by Dr. Tomisaku Kawasaki in Japan in 1967, the disease occurs globally with the highest incidence in children of East Asian descent (especially Japanese and Korean ancestry).

• Epidemiological Profile: Approximately 80% to 85% of cases occur in children between 6 months and 5 years of age, with a peak incidence between 18 and 24 months. It is rare in infants under 3 months (likely due to protective maternal antibodies) and in children over 8 years.
• Pathogenesis: Although the precise etiology remains elusive, current evidence points to an infectious respiratory trigger that incites an abnormal genetically determined hyperinflammatory immune cascade in susceptible children. Pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) activate endothelial cells, driving an infiltration of neutrophils followed by CD8+ T lymphocytes, IgA-producing plasma cells, and macrophages into the coronary arterial wall. This induces destruction of the internal elastic lamina, medial necrosis, smooth muscle proliferation, and progressive structural weakening, culminating in coronary artery aneurysm (CAA) formation, thrombosis, or stenosis.

---

Diagnostic Criteria for Classic Kawasaki Disease

No single laboratory assay is pathognomonic; Kawasaki disease is a clinical diagnosis. AHA 2024 criteria allow complete Kawasaki disease to be diagnosed with:

• Fever for at least 4 days; do not delay diagnosis or treatment until day 5 when the principal features are present;
• PLUS at least 4 of the following 5 principal clinical features:

---

Incomplete (Atypical) Kawasaki Disease

"Incomplete" Kawasaki disease presents with fewer than four principal clinical features. Supporting laboratory or echocardiographic findings guide diagnosis; coronary abnormalities are not obligatory, and a normal early echocardiogram does not exclude KD. Young infants are particularly vulnerable to delayed diagnosis and coronary aneurysms.

• High-Risk Demographics: Infants <6 months of age and children >5 years of age. In any infant under 6 months with unexplained fever persisting for $\ge 5$ days, Kawasaki disease must be actively considered, even if few or no classic features are evident.
• Diagnostic Algorithm for Incomplete Kawasaki Disease:
  • In a child with fever $\ge 5$ days and 2 or 3 classic features (or an infant <6 months with fever $\ge 7$ days and no explanation), measure acute-phase reactants:
    • CRP $\ge 30\text{ mg/L}$ and/or ESR $\ge 40\text{ mm/hr}$.
  • If inflammatory markers are elevated, evaluate for supplementary laboratory criteria:
    1. Anemia for age (normocytic, normochromic due to acute inflammation)
    2. Platelet count $>450 \times 10^9\text{/L}$ (thrombocytosis typically emerges after day 7 of illness)
    3. Hypoalbuminemia ($\le 30\text{ g/L}$ [$\le 3.0\text{ g/dL}$] reflecting capillary leak)
    4. Elevated serum alanine aminotransferase (ALT)
    5. Leukocyte count $\ge 15 \times 10^9\text{/L}$ with prominent granulocytosis
    6. Sterile pyuria ($\ge 10\text{ WBCs/high-power field}$ on clean-catch urine, caused by non-infectious urethritis)
  • Treat when $\ge 3$ supplementary laboratory criteria are present or echocardiography is positive: LAD/RCA $Z\ge 2.5$, or $\ge 3$ suggestive findings (reduced LV function, mitral regurgitation, pericardial effusion, or LAD/RCA $Z=2$ to $<2.5$).
• BCG Scar Reactivation: In countries utilizing Bacillus Calmette-Guérin (BCG) vaccination, erythema, induration, and ulceration at the BCG inoculation site is a remarkably specific early sign of Kawasaki disease, driven by cross-reactive heat shock proteins.

---

Coronary Artery Aneurysms (CAA) and Echocardiographic Surveillance

The primary therapeutic imperative in Kawasaki disease is preventing coronary artery aneurysm formation.

• Aneurysm Incidence: Without prompt treatment, 20% to 25% of untreated children develop coronary artery dilation or aneurysms. With timely therapy initiated within the first 10 days of fever, the incidence plummets to less than 4% (and giant aneurysms drop to <1%).
• Aneurysm Stratification by Z-Scores: Coronary dimensions are normalized to body surface area and expressed as standard deviation units (Z-scores):
  • No Involvement: $Z < 2.0$
  • Dilation Only: $Z = 2.0\text{ to }<2.5$
  • Small Aneurysm: $Z = 2.5\text{ to }<5.0$
  • Medium Aneurysm: $Z = 5.0\text{ to }<10.0$ (and absolute internal diameter $<8\text{ mm}$)
  • Giant Aneurysm: $Z \ge 10.0$ (or absolute internal diameter $\ge 8\text{ mm}$)
• Echocardiographic Protocol: European SHARE follow-up includes echocardiography at diagnosis, 2 weeks after first IVIG, and 6–8 weeks after disease onset; high-risk patients or abnormal coronary findings require more frequent specialist imaging. Giant aneurysms carry risks of thrombosis, myocardial infarction and sudden death, requiring lifelong specialist follow-up. Persistent giant aneurysms generally need low-dose aspirin plus systemic anticoagulation (warfarin or LMWH); additional antiplatelet therapy is individualized.

---

Pharmacological Management Protocol for Kawasaki Disease

                                [Kawasaki Disease Diagnosed: Treat Promptly]
                                                   |
                        +--------------------------+--------------------------+
                        |                                                     |
        [High-Dose IVIG]                                        [Oral Aspirin]
     Single infusion: 2 g/kg                                Acute: 30-50 mg/kg/day (Europe)
     Infuse over 10 to 12 hours                                     until afebrile 48h
                        |                                                     |
                        |                                       Convalescent: 3-5 mg/kg/day
                        |                                       Continue for 6 to 8 weeks
                        |
             Assess at 36 Hours Post-IVIG
                        |
         +--------------+--------------+
         |                             |
  [Afebrile / Improved]     [Persistent/Recrudescent Fever >= 36h]
         |                             |
   Discharge on Aspirin        [IVIG-Resistant Disease (10-20%)]
                                       |
                             Second IVIG (2 g/kg)
                             OR IV Methylprednisolone (30 mg/kg/d x 3d)
                             OR Infliximab (10 mg/kg IV)

Core Pharmacotherapy

1. Intravenous Immunoglobulin (IVIG):
   • Dose: 2 g/kg administered as a single, uninterrupted intravenous infusion over 10 to 12 hours.
   • Timing: Treat promptly, ideally within 10 days of fever; persistent unexplained fever or ongoing inflammation can warrant IVIG after day 10. At diagnosis, infants <6 months or patients with coronary Z≥2.5 should be considered for IVIG plus adjunctive anti-inflammatory therapy with specialist guidance.
   • Mechanism: Rapidly neutralizes circulating pathogenic antigens, accelerates catabolism of host antibodies via Fc receptor saturation, and suppresses pro-inflammatory cytokine expression.
2. Oral Aspirin (Acetylsalicylic Acid):
   • Acute Febrile Phase: European SHARE uses 30–50 mg/kg/day orally in 3–4 divided doses. AHA guidance describes either moderate-dose 30–50 mg/kg/day or high-dose 80–100 mg/kg/day regimens. Continue until the patient has remained afebrile for at least 48 to 72 hours.
   • Convalescent Antiplatelet Phase: Once afebrile, transition to low-dose antiplatelet aspirin: 3 to 5 mg/kg/day as a single daily dose. Continue for 6 to 8 weeks post-onset. If follow-up echocardiography at 6 to 8 weeks confirms completely normal coronary arteries and normalized inflammatory markers, aspirin is discontinued.

IVIG-Resistant Disease

Approximately 10% to 20% of patients experience IVIG resistance, defined as persistent or recrudescent fever $\ge 36$ hours after completion of the initial IVIG infusion. These patients are at markedly increased risk for coronary aneurysms.

• Second-Line Therapeutic Options:
  • A second dose of IVIG (2 g/kg infusion);
  • Pulse intravenous Methylprednisolone (30 mg/kg/day IV for 3 consecutive days);
  • Infliximab (10 mg/kg IV over 2 hours, AHA 2024), a chimeric monoclonal antibody targeting TNF-alpha.

Critical Clinical Cautions with Kawasaki Therapy

• Live-Attenuated Vaccine Deferral: High-dose IVIG provides high titers of passively acquired measles, mumps, rubella, and varicella antibodies that neutralize live-virus vaccines. Administration of the MMR and Varicella vaccines must be deferred for 11 months following high-dose IVIG therapy.
• Reye Syndrome Risk: Children receiving ongoing aspirin therapy who contract influenza or varicella are at risk for Reye syndrome (acute hepatic failure and encephalopathy). Annual inactivated influenza vaccination is mandatory for all children receiving prolonged aspirin regimens.

---

Acute Rheumatic Fever (ARF)

Acute Rheumatic Fever is a delayed, non-suppurative, multi-system autoimmune sequela resulting from untreated pharyngeal infection with Group A Streptococcus (GAS; Streptococcus pyogenes).

Pathophysiological Mechanism: Molecular Mimicry

ARF does not represent a direct bacterial invasion of the heart. Instead, infection by rheumatogenic strains of GAS triggers antibodies against bacterial surface antigens—specifically M protein and N-acetyl-beta-D-glucosamine. Because of structural homology (molecular mimicry), these antibodies and primed CD4+ T lymphocytes cross-react with human host tissue antigens, including cardiac myosin, laminin, synovial proteoglycans, and basal ganglia neuronal cells. This incites immune-mediated pancarditis, sterile migratory synovitis, and neurological dysfunction.

The Revised Jones Criteria Framework

For an initial episode, diagnosis usually requires evidence of preceding GAS infection, PLUS the following combination. Late isolated chorea or indolent carditis may be diagnosed without demonstrable recent GAS infection or the full combination, after excluding other causes:

• Two Major Criteria, OR
• One Major Criterion + Two Minor Criteria.

Detailed Analysis of Major Manifestations

• Carditis (50–60% of cases): The only manifestation of ARF that produces chronic, permanent organ damage. Characteristically presents as an active valvulitis, resulting in mitral regurgitation (apical holosystolic murmur radiating to the axilla) and occasionally aortic regurgitation (early diastolic murmur at the upper left sternal border). Echocardiography detects subclinical carditis (pathological valvular regurgitation) even when murmurs are not appreciated by auscultation.
• Migratory Polyarthritis (75% of cases): Typically affects large joints (knees, ankles, elbows, wrists) in an asymmetrical, fleeting pattern—one joint becomes acutely hot, swollen, and exquisitely tender for a few days, then improves spontaneously as another joint inflames. Joint symptoms show a dramatic, almost diagnostic response to aspirin or NSAIDs within 24 to 48 hours.
• Sydenham Chorea (10–15%): Occurs after a prolonged latent period of 1 to 6 months post-streptococcal infection. Characterized by rapid, purposeless, non-rhythmic involuntary movements of the face and extremities, muscle weakness ("milkmaid's grip", pronator sign), and emotional lability. Resolves spontaneously over 2 to 6 months.
• Erythema Marginatum (<5%): An evanescent, non-pruritic, pink maculopapular eruption with sharp erythematous serpentine borders and central clearing. Primarily involves the trunk and proximal extremities, strictly sparing the face. Accentuated by heat (e.g., a warm bath).
• Subcutaneous Nodules (<5%): Firm, painless, pea-sized nodules (0.5–2 cm) located over extensor tendons and bony prominences (elbows, knees, occiput, vertebrae). Strongly correlated with severe, progressive carditis.

Acute Medical Management of ARF

1. GAS Eradication: Administer a single intramuscular dose of Benzathine Benzylpenicillin (600,000 units for children $<27\text{ kg}$; 1.2 million units for $\ge 27\text{ kg}$) or a 10-day course of oral Phenoxymethylpenicillin.
2. Anti-inflammatory Therapy:
   • Isolated Arthritis / Mild Carditis: Oral Aspirin (50 to 60 mg/kg/day, up to 80–100 mg/kg/day in 4 divided doses) or Naproxen (15 mg/kg/day) until symptoms resolve and inflammatory markers normalize.
   • Moderate-to-Severe Carditis (with cardiomegaly or heart failure): Oral Prednisolone (1 to 2 mg/kg/day, maximum 60 mg/day) for 2 to 4 weeks, followed by a gradual taper while overlapping with aspirin to prevent rebound carditis.
3. Heart Failure Therapy: Fluid restriction, furosemide, and ACE inhibitors (enalapril) for decompensated ventricular dysfunction.

Secondary Antibiotic Prophylaxis: Regimens and Durations

To prevent recurrent GAS pharyngitis and cumulative valvular destruction, every patient with a documented history of ARF mandates ongoing secondary penicillin prophylaxis.

• Preferred Regimen: Intramuscular Benzathine Penicillin G administered every 3 to 4 weeks (every 3 weeks is recommended in high-risk geographic areas). Oral Penicillin V (250 mg twice daily) is an inferior second-line option due to poor compliance.
• Prophylaxis Duration Guidelines:
  • ARF without Carditis: Minimum of 5 years after the last acute attack, or until the patient reaches 21 years of age, whichever is longer.
  • ARF with Carditis but No Persistent Valvular Disease: Minimum of 10 years after the last attack, or until 21 years of age, whichever is longer.
  • ARF with Carditis and Persistent Residual Valvular Disease: Minimum of 10 years after the last attack, or until 40 years of age (and often lifelong if occupational exposure risk is high).

---

Infective Endocarditis (IE)

• Risk factors: congenital heart disease, especially unrepaired cyanotic lesions and repairs using prosthetic material such as conduits or shunts; prosthetic valves; previous IE; and indwelling central venous catheters.
• Organisms: Staphylococcus aureus and oral (viridans group) streptococci are most common, followed by coagulase-negative staphylococci, enterococci and the HACEK group.
• Presentation: prolonged fever, malaise and weight loss with a new or changing murmur, heart failure, embolic events (stroke, splenic or renal infarcts, septic pulmonary emboli in right-sided disease), splenomegaly, haematuria and vascular or immunological signs such as splinter haemorrhages, Osler nodes, Janeway lesions and Roth spots.
• Investigations: take at least three sets of blood cultures at 30-minute intervals before antibiotics. Echocardiography is the first-line imaging test; transoesophageal echocardiography is used when transthoracic images are inconclusive or complications are suspected. Diagnostic criteria combine microbiology and imaging.
• Treatment: prolonged intravenous bactericidal therapy, usually for several weeks, guided by the organism; surgery for heart failure, uncontrolled infection or a high embolic risk.
• Prophylaxis (ESC 2023): give antibiotic prophylaxis only to highest-risk patients — previous IE; prosthetic valves or valve-repair material; untreated cyanotic congenital heart disease and congenital repairs with prosthetic material such as valved conduits or systemic-to-pulmonary shunts; after septal-defect closure devices, the risk is mainly within the first 6 months. Prophylaxis covers dental extractions, oral surgery and procedures manipulating the gingival or periapical region. Children receive one dose of amoxicillin 50 mg/kg (maximum 2 g) 30–60 minutes before the procedure; with penicillin allergy, azithromycin or clarithromycin 15 mg/kg (maximum 500 mg) can be used. Clindamycin is no longer recommended. Good oral hygiene and regular dental review matter for every at-risk child.

Source: 2023 ESC Guidelines for the management of endocarditis.